Fat-derived cell injection for osteoarthritis of the lower back facet joints
Tests cells taken from body fat against corticosteroid in facet joint osteoarthritis.
Key facts
- Who runs it
- InGeneron, Inc.
- Where
- Deerfield Beach and Sioux Falls, United StatesSee the 2 sites
- Trial code
- Registry title
- Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 7 Dec 2018
- Planned end
- Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Adipose-derived stem cell injection
- Corticosteroid injection
- Record updated
- 20 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term low back pain caused by osteoarthritis (wear) of the facet joints in the lower spine. It compares an injection of cells taken from the person's own fat with a corticosteroid injection.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- Facet joint osteoarthritis from L1 to S1, seen on X-ray. Low back pain for at least 6 months, with a pain score of at least 4 on a 0-10 scale. Pain must ease by more than 80% after a test injection.
- Earlier treatment
- Must have tried 3 months of non-surgical back care without success, and supervised physical therapy. No epidural steroid injection, facet joint injection, nerve block or nerve ablation in the 8 weeks before. No earlier stem cell therapy for the spine.
Main reasons for not taking part
- Pregnant or breastfeeding, or planning pregnancy within 12 months
- BMI over 40
- Cancer within the last 2 years, except some fully removed skin or cervix cancers
- Nerve pain down the leg, narrowing of the spinal canal, or a spine fracture
- Taking drugs that weaken the immune system, long-term tobacco or nicotine use, or opioid use over 40mg/day morphine equivalent
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Male and female subjects, between 18 and 75 years of age
- Have documented the diagnosis of facet joint osteoarthritis from L1 to S1 in the opinion of the investigator
- Have a documented diagnosis of symptomatic facet joint syndrome is defined as the following (subject must meet all the listed conditions):; Chronic low back pain for at least 6 months; Have failed 3 months of conservative back pain care. (Conservative treatment regimens may include any or all of the following: initial rest, medications [e.g., anti-inflammatory, analgesics, narcotics/opioids, muscle relaxants], massage, acupuncture, chiropractic manipulations, activity modification, home-directed lumbar exercise program, and non- invasive pain control treatments or procedures); Have undergone supervised physical therapy, such as daily walking routines, therapeutic exercises, and back education programs specifically for the treatment of low back pain; Change from normal spine morphology at the symptomatic level as defined by Radiographic evaluation for Lumbar facet joint osteoarthritis; The baseline pain score of at least 4 on a pain scale of 0-10, over 24 hours
- Subjects demonstrate >80% relief of their pain after diagnostic injection
- Signed informed consent indicating the subject is willing to undergo treatment and willing to be available for each examination scheduled over the study duration
Who cannot take part
- Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, congenital sterility or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least one months prior to study entry
- Any lumbar intradiscal injection, including steroids, at the symptomatic or adjacent discs less than 3 months prior to treatment injection, except for the following injections performed at least 2 weeks prior to study treatment:; Contrast medium (discography or other diagnostic injection); NSAIDs; Nerve-blocking anesthetics (e.g., lidocaine, bupivacaine); Antibiotics; Saline
- Epidural steroid injections, prior lumbar facet joint injection, medial branch block or radiofrequency ablation of facet joint nerves within 8 weeks prior to treatment injection
- Have received chronic (more than 7 consecutive days) treatment with systemic corticosteroids at a dose equivalent to prednisone ≥ 10 mg/day within 14 days prior to an injection procedure
- Have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any indication or autologous stem cell/progenitor cell therapy or other biological intervention to repair the target intervertebral disc or facet joint
- Current infection or prior history of spinal infection at the symptomatic level (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection
- Receiving workman's compensation unless litigation is complete
- The subject is receiving immunosuppressant therapy or has a known immunologic or severe autoimmune disease that requires chronic immunosuppressive or immunomodulatory therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, rheumatoid arthritis, etc.)
- Clinically significant, in the opinion of the investigator, nerve pain (e.g., chronic radiculopathy) or clinically significant sacroiliac joint pain based on targeted, pre-specified physical examination, and, if deemed medically necessary, confirmed by anesthetic injection. If a previously performed anesthetic injection to confirm SI joint pain was performed up to 6 months prior to injection (with documentation indicating no SI joint pain), this does not need to be repeated at screening
- Severe instability where, in the opinion of the investigator, surgical interventions to stabilize the segment would be required
- Active malignancy or tumor as a source of symptoms or history of malignancy within the 2 years prior to enrollment on the study, except history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or squamous cell carcinoma of the cervix if fully excised and with clear margins
- Are at a higher risk, in the opinion of the investigator, for bleeding (e.g., bleeding disorder, or taking anticoagulants, except low dose aspirin) or infection (e.g., taking immunosuppressants, have a severe infection, or a history of serious infection)
- Severe and/or chronic pain conditions that may potentially confound facet joint symptom assessment, in the opinion of the investigator
- Cauda equina syndrome
- Subjects with documented history of alcohol or drug abuse within the last year
- History of Chronic tobacco and nicotine usage
- Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention
- Subjects who have document allergy to radiographic agents or sodium citrate or any "caine" type of local anesthetic
- Female subjects who are pregnant or nursing, or women planning to become pregnant within 12 months following treatment
- Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI > 40)
- Subject is currently participating in another clinical trial that has not yet completed its primary endpoint
- An average baseline morphine equivalent dose (MED) of >40mg/day collected during the screening visit
- Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. This includes completion of patient reported outcome instruments
- Body habitus precluding adequate fluoroscopic visualization for the procedure or the procedure is physically impossible due to inability to inject the facet joint
- Failed any component of the lumbar neurological exam at baseline (i.e., motor, sensory, or a reflex portion of the exam)
- Symptomatic lumbar intervertebral foraminal stenosis at the symptomatic level resulting in clinically significant spinal nerve root compression, in the opinion of the investigator
- Symptomatic central vertebral canal, lateral recess stenosis or foraminal stenosis, in the opinion of the investigator
- An acute fracture of the spine. Clinically compromised, in the opinion of the investigator, vertebral bodies at the symptomatic level due to current or past trauma, e.g., sustained a pathological fracture or multiple fractures of vertebrae
- Insufficient amount of subcutaneous tissue to allow recovery of at least 100 mL of adipose tissue
- Subjects with radicular leg pain as determined by investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Sports and Orthopedic CenterDeerfield Beach, United StatesContact: Ahmad NasriTaking people
- Sanford Physical Medicine & Rehabilitation Clinic and Sanford Spine CenterSioux Falls, United StatesContact: Brian CaballeroNo longer taking part
About the trial
What the trial wants to find out
This is a prospective, randomized, active controlled, single site safety and efficacy study in subjects suffering from chronic lumber back pain due to facet joint osteoarthritis comparing a single ADRC injection generated with the Transpose® RT system into the facet joint.
The 2 groups in the trial
- Adipose-derived stem cell injectionTreatment being tested
ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
- Corticosteroid injectionExisting treatment, for comparison
The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Injection of Adipose-derived Regenerative Cells (ADRCs) in Patients Suffering From Osteoarthritis of the Facet Joints
- Plain-language title
- Fat-derived cell injection for osteoarthritis of the lower back facet jointsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT03513731, who can take part
- Record updated
- 20 August 2025